Jiangsu, China

Zuyin Du

This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignee: Jiangsu Hansoh Pharmaceutical Group Co., Ltd.. Active years: 2019-2020.


 

Average Co-Inventor Count = 5.5

ph-index = 1


Company Filing History:


Years Active: 2019-2020

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations of Zuyin Du in Pharmaceutical Development

Introduction

Zuyin Du is a prominent inventor based in Jiangsu, China, known for his significant contributions to the pharmaceutical industry. He has been instrumental in developing innovative methods and formulations that enhance the quality and efficacy of medications.

Latest Patents

Zuyin Du holds two notable patents. The first patent is titled "Crystal form of dapagliflozin intermediate and preparation method therefor." This invention discloses a highly purified crystal form of a dapagliflozin intermediate, achieving a purity of 99.3% or more. This advancement is crucial for improving the quality of dapagliflozin, with a preparation process that is simple and suitable for industrial production. The second patent, "Dapagliflozin crystal form and preparation method and use thereof," introduces a new crystal form E of 2-chloro-5-(β-D-glucopyranose-1-yl)-4'-ethyoxyldiphenylmethane. This patent also details a preparation method and its use in treating type II diabetes, showcasing the therapeutic potential of the new crystal form.

Career Highlights

Zuyin Du is affiliated with Jiangsu Hansoh Pharmaceutical Group Co., Ltd., where he has made significant strides in pharmaceutical research and development. His work focuses on enhancing drug formulations and improving therapeutic outcomes for patients.

Collaborations

Zuyin Du collaborates with esteemed colleagues, including Xiang Li and Jun Yu, who contribute to his research efforts and innovations in the pharmaceutical field.

Conclusion

Zuyin Du's innovative work in the development of dapagliflozin intermediates and crystal forms exemplifies his commitment to advancing pharmaceutical science. His contributions are vital for improving treatment options for patients with type II diabetes.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…